Vor Biopharma Inc. (NASDAQ:VOR) Receives $42.25 Consensus Price Target from Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $42.25.

VOR has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush raised their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. sold 171,963 shares of Vor Biopharma stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51. Following the completion of the transaction, the director directly owned 2,567,245 shares of the company’s stock, valued at $40,485,453.65. This trade represents a 6.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 28,408.1% in the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after acquiring an additional 112,496 shares during the period. Irenic Capital Management LP bought a new stake in shares of Vor Biopharma during the 1st quarter valued at about $583,000. Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma during the 1st quarter valued at about $2,298,000. Sei Investments Co. bought a new position in shares of Vor Biopharma in the 1st quarter worth approximately $245,000. Finally, Independent Financial Group LLC purchased a new position in shares of Vor Biopharma in the first quarter worth approximately $249,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

NASDAQ VOR opened at $18.09 on Wednesday. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $53.00. The business’s 50-day moving average is $15.94 and its 200 day moving average is $15.01.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, research analysts predict that Vor Biopharma will post -2.51 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).